NCT07003347 (REACH) is a NA clinical trial of oral spray of MgCl2 in Chronic Cough, sponsored by Kholood Altassan.

Who is sponsoring NCT07003347?

NCT07003347 is sponsored by Kholood Altassan.

What drugs are being tested in NCT07003347?

Interventions in NCT07003347: oral spray of MgCl2, Saline.

What condition does NCT07003347 study?

NCT07003347 studies Chronic Cough.

Is NCT07003347 still recruiting?

NCT07003347 is currently completed. Last updated 21 January 2026.

Last reviewed 2026-01-21 · How we verify

NCT07003347: REACH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Investigate the Efficacy and Safety of SC0023, in Adults With Refractory or Unexplained Chronic Cough

Completed NA Last updated 21 January 2026

What this trial tests

NA trial testing oral spray of MgCl2 in Chronic Cough in 7 participants. Completed in 30 August 2025.

Timeline

19 December 2024

Primary endpoint
30 July 2025

30 August 2025

Quick facts

Lead sponsor	Kholood Altassan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	7
Start date	19 December 2024
Primary completion	30 July 2025
Estimated completion	30 August 2025
Sites	1 location across Saudi Arabia

Drugs / interventions tested

oral spray of MgCl2
Saline

Conditions studied

Chronic Cough — all drugs for Chronic Cough →

Sponsor

Kholood Altassan

Who can join

Adults 18 to 80, any sex, with Chronic Cough. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, placebo controlled cross-over study to investigate the efficacy and safety of SC0023 (an oral spray of magnesium based alkaline hypertonic divalent salt) in adults with refractory or unexplained chronic cough over 14 days. Approximately 20 participants being enrolled and randomized into the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Cough

Currently open trials in the same condition.

NCT07488598 — Efficacy of Behavioral Therapy for Chronic Refractory Cough · NA · recruiting
NCT06542484 — The Real-world Treatment Satisfaction by Gefapixiant in RCC · NA · recruiting
NCT05813223 — Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough · EARLY_PHASE1 · recruiting
NCT06286163 — Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients · recruiting
NCT05362097 — Analysis of the Reliability and Validity of the Chinese Version of CC-QoL · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07003347 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kholood Altassan
Last refreshed: 21 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07003347.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing